Figure 11.

Effects of n-3 LC-PUFAs vs a control on NAS, assessed histologically, in patients with NASH. A random-effects model was used to calculate the pooled estimate of the differences in means and the accompanying 95%CI. Studies were weighted by the inverse of their variance; the area of each symbol is proportional to the weight of the study. The diamond represents the pooled effect. The pooled change from baseline in NAS with intake of n-3 LC-PUFAs, corrected for changes from baseline in the control group, is 0.56 (95%CI, −0.12 to 1.23; P=0.105). Using the trim and fill method of Duval and Tweedie,³⁵ no studies were found to be missing to the right of the mean effect. Abbreviations: DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; n-3 LC-PUFAs, omega-3 long-chain polyunsaturated fatty acids; NAS, nonalcoholic fatty liver disease activity score; NASH, nonalcoholic steatohepatitis; T2DM, type 2 diabetes mellitus.